Lunada Biomedical v. Nunez

230 Cal. App. 4th 459, 178 Cal. Rptr. 3d 784, 2014 Cal. App. LEXIS 904
CourtCalifornia Court of Appeal
DecidedOctober 9, 2014
DocketB243205, B246602
StatusPublished
Cited by48 cases

This text of 230 Cal. App. 4th 459 (Lunada Biomedical v. Nunez) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lunada Biomedical v. Nunez, 230 Cal. App. 4th 459, 178 Cal. Rptr. 3d 784, 2014 Cal. App. LEXIS 904 (Cal. Ct. App. 2014).

Opinion

Opinion

MOSK, J.

INTRODUCTION

Attorneys for a consumer served on a company a notice required for damages under the Consumers Legal Remedies Act, Civil Code section 1750 et seq. (CLRA), setting forth alleged violations of the CLRA and demanding action. The company then brought a declaratory relief action against the consumer and her attorneys seeking a declaration that it had not violated the CLRA. The consumer and the attorneys moved to strike the complaint under Code of Civil Procedure section 425.16 1 *466 (anti-SLAPP statute), 2 which motions the trial court granted. In affirming, we hold that the declaratory relief action is subject to the anti-SLAPP statute as it arose out of protected activity provided by that statute, and that the trial court properly granted the special motions to strike because the company’s declaratory relief action had no probability of success. In this connection, we hold that under the reasoning of Filarsky v. Superior Court (2002) 28 Cal.4th 419 [121 Cal.Rptr.2d 844, 49 P.3d 194] (Filarsky), a potential defendant in a CLRA damages action after receiving the statutory notice may not maintain a declaratory relief action to establish that there was no violation of the CLRA. We therefore affirm the order striking the complaint. We also affirm the award of attorney fees.

FACTUAL AND PROCEDURAL BACKGROUND

Laura Nunez (Nunez) retained two law firms, Newport Trial Group (Newport) and Wasserman, Comden, Casselman & Esensten, LPP (Wasserman) 3 to represent her in an anticipated consumer class action under the CLRA. Newport served Lunada Biomedical (plaintiff) with a one-page notice and demand, pursuant to Civil Code section 1782 of the CLRA (CLRA Notice), via certified mail, return receipt requested, contending that plaintiff’s dietary supplement, Amberen, was being marketed falsely and misleadingly as a “natural remedy for Menopausal symptom relief,” in violation of the CLRA. The CLRA Notice was served on behalf of an unnamed Californian individual and a class of similarly situated persons. It requested that plaintiff “irrevocably stop all false, misleading, and/or unsubstantiated advertising and labeling claims, and provide all consumers who have purchased Amberen with a full refund.” Plaintiff’s counsel responded by letter to the CLRA Notice, denying its contentions, and claiming in detail that scientific evidence supported plaintiff’s advertising claims concerning Amberen.

Thereafter, plaintiff’s counsel sent an e-mail to Wasserman confirming their telephone conversation that occurred a few days previously, stating that he disagreed with Wasserman’s claims for the reasons set forth in plaintiff’s earlier reply letter, and stating, “[A]s I mentioned, I almost always consider settlement issues before litigation, so I asked you to propose a settlement offer. . . . There’s no rush, we can talk whenever you are ready.” Later that afternoon, an attorney from Wasserman sent an e-mail to plaintiff’s counsel, stating, “Given the upcoming holidays, I have not had a chance to talk to all interested parties, much less put together a ‘settlement offer.’ ” The e-mail also stated that Wasserman needed information regarding the sale of Amberen before it could propose a settlement demand, but that it would provide *467 plaintiff’s counsel with an outline of the injunctive relief concerning “labeling and advertising changes” that “we” would demand as part of any settlement.

A little over a month later, the attorney from Wasserman sent an 11-page letter to plaintiff’s counsel via e-mail and United States mail thanking him for responding to “our [CLRA Notice] on behalf of our client, . . . Nunez . . . regarding her potential class action claims related to Amberen ...” The letter stated, “In accordance with our November 18th telephone conversation and subsequent email communications, this letter will discuss possible ways to resolve the current dispute concerning our client’s false and misleading advertising claims against [plaintiff], I will not attempt to further address the merits of [Nunez’s] claims in this letter. Instead, I will simply outline briefly potential settlement approaches and structures.” It set forth possible “ALTERNATIVE SETTLEMENT STRUCTURES,” and detailed matters subject to injunctive relief consisting of “PROPOSED ADVERTISING AND MARKETING MODIFICATIONS.” The proposed advertising and marketing modifications were matters that, according to Wasserman, plaintiff should “permanently cease” from representing to current and potential purchasers of Amberen, “delete” from all Amberen advertising and labeling, and include in all future Amberen advertising and labeling.

Within two weeks, plaintiff filed a complaint alleging a single cause of action for declaratory relief against defendants. Plaintiff sought a determination regarding “the accuracy and legality” of plaintiff’s advertising of Amberen. Plaintiff alleged in its complaint that “[t]his action is being filed because Defendants threaten to file a lawsuit claiming that Plaintiff’s advertising violates California’s consumer protection statutes, including . . . [the CLRA]. However, Defendants’ threatened suit lacks any basis . . . .” Plaintiff alleged in the complaint that “[t]his dispute was originally raised in a [CLRA Notice] claiming that [plaintiff’s] advertising for Amberen supposedly violated the CLRA ...” Plaintiff also referred to in the complaint various additional communications the parties had regarding settlement, including Wasserman’s letter. Plaintiff also included in the complaint responses to the matters contained in Wasserman’s letter.

Nunez and Newport filed an anti-SLAPP motion, in which Wasserman joined. The motions were made on the grounds that plaintiff’s claim arose from protected activity—“defendants’ CLRA [N]otice regarding plaintiff’s deceptive advertising claims about its product Amberen, and related settlement communications”—and that plaintiff could not establish a probability of prevailing on its claim.

Plaintiff opposed defendants’ anti-SLAPP motions. In support of that opposition, plaintiff provided substantial evidence in support of its contention *468 that its advertising of Amberen was not false and misleading. Specifically, plaintiff submitted a declaration attaching plaintiff’s counsel’s letter setting forth scientific evidence that supported plaintiff’s advertising claims concerning Amberen and declarations of a professor in biology from the department of life sciences at Santa Monica College and of a deputy director and head of the laboratory of the Institute of Theoretical and Experimental Biophysics of the Russian Academy of Science, both of which declarations asserted in detail that scientific evidence supported plaintiff’s advertising claims concerning Amberen. Defendants objected to plaintiff’s evidence. 4

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dingizian v. Cruz CA2/7
California Court of Appeal, 2026
City of Santa Monica v. Sung CA2/4
California Court of Appeal, 2026
Skytte v. Skytte CA4/3
California Court of Appeal, 2026
Panzak v. City of Fowler CA5
California Court of Appeal, 2025
Roe v. Cordoba CA2/4
California Court of Appeal, 2025
Haas v. Littleton CA2/7
California Court of Appeal, 2025
Weather Group v. McDonald's USA CA2/2
California Court of Appeal, 2025
Wang v. Plaza Bonita CA2/2
California Court of Appeal, 2025
Polaris Blue Holdings v. Friedman CA2/4
California Court of Appeal, 2025
Wastexperts, Inc. v. Arakelian Enterprises, Inc.
California Court of Appeal, 2024
Petersen v. Feldman CA4/2
California Court of Appeal, 2024
Thompson v. Ito CA4/3
California Court of Appeal, 2024
Rosen & Associates, P.C. v. Meruelo CA2/7
California Court of Appeal, 2023
Hernandez v. Luna CA4/2
California Court of Appeal, 2022
Larson v. Roberts CA6
California Court of Appeal, 2022
Veeva Systems v. Medidata Solutions CA1/3
California Court of Appeal, 2022
Vines v. O'Reilly Auto Enterprises, LLC
California Court of Appeal, 2022

Cite This Page — Counsel Stack

Bluebook (online)
230 Cal. App. 4th 459, 178 Cal. Rptr. 3d 784, 2014 Cal. App. LEXIS 904, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lunada-biomedical-v-nunez-calctapp-2014.